Literature DB >> 26648515

Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses.

Charles J Russell1,2, Julia L Hurwitz1,2.   

Abstract

Human paramyxoviruses are the etiological agents for life-threatening respiratory virus infections of infants and young children. These viruses, including respiratory syncytial virus (RSV), the human parainfluenza viruses (hPIV1-4) and human metapneumovirus (hMPV), are responsible for millions of serious lower respiratory tract infections each year worldwide. There are currently no standard treatments and no licensed vaccines for any of these pathogens. Here we review research with which Sendai virus, a mouse parainfluenza virus type 1, is being advanced as a Jennerian vaccine for hPIV1 and as a backbone for RSV, hMPV and other hPIV vaccines for children.

Entities:  

Keywords:  Sendai virus; T cell; antibody; intranasal; paramyxovirus; pediatric vaccine; respiratory tract; vaccine vector

Mesh：

Substances：

Year:  2015        PMID： 26648515      PMCID： PMC4957581          DOI： 10.1586/14760584.2016.1114418

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN： 1476-0584            Impact factor:   5.217


  129 in total

1.  Susceptibility of inbred and outbred mouse strains to Sendai virus and prevalence of infection in laboratory rodents.

Authors:  J C Parker; M D Whiteman; C B Richter
Journal:  Infect Immun       Date:  1978-01       Impact factor: 3.441

Review 2.  Antigen processing and presentation by the class I major histocompatibility complex.

Authors:  I A York; K L Rock
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

3.  Identification of biological activities of paramyxovirus glycoproteins. Activation of cell fusion, hemolysis, and infectivity of proteolytic cleavage of an inactive precursor protein of Sendai virus.

Authors:  A Scheid; P W Choppin
Journal:  Virology       Date:  1974-02       Impact factor: 3.616

4.  Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody.

Authors:  Jason S McLellan; Man Chen; Sherman Leung; Kevin W Graepel; Xiulian Du; Yongping Yang; Tongqing Zhou; Ulrich Baxa; Etsuko Yasuda; Tim Beaumont; Azad Kumar; Kayvon Modjarrad; Zizheng Zheng; Min Zhao; Ningshao Xia; Peter D Kwong; Barney S Graham
Journal:  Science       Date:  2013-04-25       Impact factor: 47.728

5.  Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.

Authors:  Matthew R Murawski; Lori W McGinnes; Robert W Finberg; Evelyn A Kurt-Jones; Michael J Massare; Gale Smith; Penny M Heaton; Armando E Fraire; Trudy G Morrison
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

6.  A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age.

Authors:  Gregory M Glenn; Louis F Fries; D Nigel Thomas; Gale Smith; Eloi Kpamegan; Hanxin Lu; David Flyer; Dewal Jani; Somia P Hickman; Pedro A Piedra
Journal:  J Infect Dis       Date:  2015-08-10       Impact factor: 5.226

7.  Burden of human metapneumovirus infection in young children.

Authors:  Kathryn M Edwards; Yuwei Zhu; Marie R Griffin; Geoffrey A Weinberg; Caroline B Hall; Peter G Szilagyi; Mary A Staat; Marika Iwane; Mila M Prill; John V Williams
Journal:  N Engl J Med       Date:  2013-02-14       Impact factor: 91.245

Review 8.  Development of an AIDS vaccine using Sendai virus vectors.

Authors:  Hiroshi Ishii; Tetsuro Matano
Journal:  Vaccine       Date:  2015-07-29       Impact factor: 3.641

9.  Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzees.

Authors:  Mario H Skiadopoulos; Sonja R Surman; Jeffrey M Riggs; William R Elkins; Marisa St Claire; Machiko Nishio; Dominique Garcin; Daniel Kolakofsky; Peter L Collins; Brian R Murphy
Journal:  Virology       Date:  2002-05-25       Impact factor: 3.616

10.  Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children.

Authors:  Ruth A Karron; Bhagvanji Thumar; Elizabeth Schappell; Sonja Surman; Brian R Murphy; Peter L Collins; Alexander C Schmidt
Journal:  Vaccine       Date:  2011-12-14       Impact factor: 3.641
View more
  20 in total

Review 1.  Vaccine Design Informed by Virus-Induced Immunity.

Authors:  Rhiannon R Penkert; Jane S Hankins; Neal S Young; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-05-05       Impact factor: 2.257

2.  Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.

Authors:  Bo Liang; Joan O Ngwuta; Richard Herbert; Joanna Swerczek; David W Dorward; Emerito Amaro-Carambot; Natalie Mackow; Barbora Kabatova; Matthias Lingemann; Sonja Surman; Lijuan Yang; Man Chen; Syed M Moin; Azad Kumar; Jason S McLellan; Peter D Kwong; Barney S Graham; Anne Schaap-Nutt; Peter L Collins; Shirin Munir
Journal:  J Virol       Date:  2016-10-14       Impact factor: 5.103

Review 3.  Vaccines for the Paramyxoviruses and Pneumoviruses: Successes, Candidates, and Hurdles.

Authors:  Charles J Russell; Eric A F Simões; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2018-01-11       Impact factor: 2.257

Review 4.  T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.

Authors:  Anne Monette; Andrew J Mouland
Journal:  Int Rev Cell Mol Biol       Date:  2018-10-24       Impact factor: 6.813

5.  A Sendai virus recombinant vaccine expressing a gene for truncated human metapneumovirus (hMPV) fusion protein protects cotton rats from hMPV challenge.

Authors:  Charles J Russell; Bart G Jones; Robert E Sealy; Sherri L Surman; John N Mason; Randall T Hayden; Ralph A Tripp; Toru Takimoto; Julia L Hurwitz
Journal:  Virology       Date:  2017-06-09       Impact factor: 3.616

6.  Low Retinol-Binding Protein and Vitamin D Levels Are Associated with Severe Outcomes in Children Hospitalized with Lower Respiratory Tract Infection and Respiratory Syncytial Virus or Human Metapneumovirus Detection.

Authors:  Julia L Hurwitz; Bart G Jones; Rhiannon R Penkert; Shane Gansebom; Yilun Sun; Li Tang; Anna M Bramley; Seema Jain; Jonathan A McCullers; Sandra R Arnold
Journal:  J Pediatr       Date:  2017-05-31       Impact factor: 4.406

7.  Efficient Delivery of Human Cytomegalovirus T Cell Antigens by Attenuated Sendai Virus Vectors.

Authors:  Richard Kiener; Markus Fleischmann; Marian Alexander Wiegand; Niels A W Lemmermann; Christiane Schwegler; Christine Kaufmann; Angelique Renzaho; Simone Thomas; Eva Felder; Hans Helmut Niller; Benedikt Asbach; Ralf Wagner
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

8.  Vaccines against respiratory syncytial virus: The time has finally come.

Authors:  Barney S Graham
Journal:  Vaccine       Date:  2016-05-13       Impact factor: 3.641

9.  Sialoglycovirology of Lectins: Sialyl Glycan Binding of Enveloped and Non-enveloped Viruses.

Authors:  Nongluk Sriwilaijaroen; Yasuo Suzuki
Journal:  Methods Mol Biol       Date:  2020

10.  A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.

Authors:  Bo Liang; Yumiko Matsuoka; Cyril Le Nouën; Xueqiao Liu; Richard Herbert; Joanna Swerczek; Celia Santos; Monica Paneru; Peter L Collins; Ursula J Buchholz; Shirin Munir
Journal:  J Virol       Date:  2020-12-22       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.